Literature DB >> 11010601

Social phobia. Epidemiology and cost of illness.

J D Lipsitz1, F R Schneier.   

Abstract

Social phobia is a prevalent and debilitating psychiatric disorder. It entails significant economic costs in the form of educational underachievement, increased financial dependency, decreased work productivity, social impairment and poorer quality of life. It is associated with increased prevalence of other psychiatric disorders including depression and alcohol dependence. Its onset is early and typically precedes onset of comorbid disorders. Despite its debilitating effects, social phobia is often unrecognised and is undertreated. The availability of efficacious pharmacological and psychotherapeutic treatments for social phobia makes it imperative to carefully consider the impact of this disorder and to consider the cost effectiveness of available treatments.

Entities:  

Mesh:

Year:  2000        PMID: 11010601     DOI: 10.2165/00019053-200018010-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  44 in total

1.  Age of onset in different phobias.

Authors:  L G Ost
Journal:  J Abnorm Psychol       Date:  1987-08

2.  Treatment of social phobia with gabapentin: a placebo-controlled study.

Authors:  A C Pande; J R Davidson; J W Jefferson; C A Janney; D J Katzelnick; R H Weisler; J H Greist; S M Sutherland
Journal:  J Clin Psychopharmacol       Date:  1999-08       Impact factor: 3.153

3.  Syndrome comorbidity in patients diagnosed with a DSM-III-R anxiety disorder.

Authors:  W C Sanderson; P A DiNardo; R M Rapee; D H Barlow
Journal:  J Abnorm Psychol       Date:  1990-08

4.  Social phobia. Comorbidity and morbidity in an epidemiologic sample.

Authors:  F R Schneier; J Johnson; C D Hornig; M R Liebowitz; M M Weissman
Journal:  Arch Gen Psychiatry       Date:  1992-04

5.  Social support deficits, loneliness and life events as risk factors for depression in old age. The Gospel Oak Project VI.

Authors:  M J Prince; R H Harwood; R A Blizard; A Thomas; A H Mann
Journal:  Psychol Med       Date:  1997-03       Impact factor: 7.723

6.  Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety.

Authors:  M B Stein; J R Walker; D R Forde
Journal:  Am J Psychiatry       Date:  1994-03       Impact factor: 18.112

7.  Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.

Authors:  J C Ballenger; G D Burrows; R L DuPont; I M Lesser; R Noyes; J C Pecknold; A Rifkin; R P Swinson
Journal:  Arch Gen Psychiatry       Date:  1988-05

8.  An examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder.

Authors:  C S Gelernter; M B Stein; M E Tancer; T W Uhde
Journal:  J Clin Psychiatry       Date:  1992-01       Impact factor: 4.384

9.  A prospective follow-along study of the course of social phobia.

Authors:  J Reich; I Goldenberg; R Vasile; R Goisman; M Keller
Journal:  Psychiatry Res       Date:  1994-12       Impact factor: 3.222

10.  Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine.

Authors:  I M van Vliet; J A den Boer; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

View more
  15 in total

Review 1.  Unmasking social anxiety disorder.

Authors:  M B Stein; J M Gorman
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Social context and the real-world consequences of social anxiety.

Authors:  Juyoen Hur; Kathryn A DeYoung; Samiha Islam; Allegra S Anderson; Matthew G Barstead; Alexander J Shackman
Journal:  Psychol Med       Date:  2019-08-19       Impact factor: 7.723

3.  Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.

Authors:  Jerome H Taylor; Angeli Landeros-Weisenberger; Catherine Coughlin; Jilian Mulqueen; Jessica A Johnson; Daniel Gabriel; Margot O Reed; Ewgeni Jakubovski; Michael H Bloch
Journal:  Neuropsychopharmacology       Date:  2017-08-29       Impact factor: 7.853

4.  Brain-derived neurotrophic factor signaling mitigates the impact of acute social stress.

Authors:  Anna M Rosenhauer; Linda Q Beach; Elizabeth C Jeffress; Brittany M Thompson; Katharine E McCann; Katherine A Partrick; Bryan Diaz; Alisa Norvelle; Dennis C Choi; Kim L Huhman
Journal:  Neuropharmacology       Date:  2018-12-14       Impact factor: 5.250

5.  Assessing social anxiety in African American youth using the social phobia and anxiety inventory for children.

Authors:  Armando A Pina; Michelle Little; Henry Wynne; Deborah C Beidel
Journal:  J Abnorm Child Psychol       Date:  2014-02

Review 6.  Social anxiety disorder in children and adolescents: epidemiology, diagnosis, and treatment.

Authors:  Sarosh Khalid-Khan; Maria-Paz Santibanez; Carolyn McMicken; Moira A Rynn
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

7.  Social phobia in Nigerian university students: prevalence, correlates and co-morbidity.

Authors:  Tolulope T Bella; Olayinka O Omigbodun
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-10-31       Impact factor: 4.328

8.  The extent of social anxiety in combination with mental disorders.

Authors:  Siebke Melfsen; Susanne Walitza; Andreas Warnke
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-03       Impact factor: 4.785

Review 9.  Issues in the assessment of social phobia: a review.

Authors:  Andrea M Letamendi; Denise A Chavira; Murray B Stein
Journal:  Isr J Psychiatry Relat Sci       Date:  2009       Impact factor: 0.481

10.  Oxytocin and Vasopressin Levels and Related Factors in Adolescents with Social Phobia and Other Anxiety Disorders.

Authors:  Necati Uzun; Ömer Faruk Akça; İbrahim Kılınç; Tevfik Balcı
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-05-31       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.